About: SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Creator	Nowotny, Norbert Loney, Tom Adrian, Thomas Al Suwaidi, Hanan Al-Marzouqi, Ahmed Alsheikh-Ali, Alawi Alsabeeha, Nabeel Kamal Eldin, Afaf Mustafa, Farah Rizvi, Tahir Senok, Abiola Stefanini, Cesare Uddin, Mohammed
Source	Medline; PMC
abstract	The COVID-19 pandemic is due to infection caused by the novel SARS-CoV-2 virus that impacts the lower respiratory tract. The spectrum of symptoms ranges from asymptomatic infections to mild respiratory symptoms to the lethal form of COVID-19 which is associated with severe pneumonia, acute respiratory distress, and fatality. To address this global crisis, up-to-date information on viral genomics and transcriptomics is crucial for understanding the origins and global dispersion of the virus, providing insights into viral pathogenicity, transmission, and epidemiology, and enabling strategies for therapeutic interventions, drug discovery, and vaccine development. Therefore, this review provides a comprehensive overview of COVID-19 epidemiology, genomic etiology, findings from recent transcriptomic map analysis, viral-human protein interactions, molecular diagnostics, and the current status of vaccine and novel therapeutic intervention development. Moreover, we provide an extensive list of resources that will help the scientific community access numerous types of databases related to SARS-CoV-2 OMICs and approaches to therapeutics related to COVID-19 treatment.
has issue date	2020-05-10(xsd:dateTime)
bibo:doi	10.3390/v12050526
bibo:pmid	32397688
has license	cc-by
sha1sum (hex)	b0c1fb537a9b077c8847c806701c3b67014572c6
schema:url	https://doi.org/10.3390/v12050526
resource representing a document's title	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
has PubMed Central identifier	PMC7290442
has PubMed identifier	32397688
schema:publication	Viruses
resource representing a document's body	covid:b0c1fb537a9b077c8847c806701c3b67014572c6#body_text
is schema:about of	named entity 'vaccine' named entity 'symptoms' named entity 'Interventions' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'The spectrum' named entity 'genomics' named entity 'molecular diagnostics' named entity 'virus' named entity 'therapeutic' named entity 'epidemiology' named entity 'development' named entity 'transcriptomic' named entity 'acute' named entity 'comprehensive' named entity 'transcriptomics' named entity 'extensive' named entity 'pathogenicity' named entity 'molecular diagnostics' named entity 'SARS-CoV-2 virus' named entity 'acute respiratory distress' named entity 'transcriptomics' named entity 'therapeutic interventions' named entity 'lower respiratory tract' named entity 'virus' named entity 'scientific community' named entity 'protein interactions' named entity 'etiology' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'virus' named entity 'RNA' named entity 'Jena' named entity 'Europe' named entity 'Middle East respiratory syndrome' named entity 'SARS' named entity 'vaccine' named entity 'airborne transmission' named entity 'Pangolin' named entity 'genetic material' named entity 'genomes' named entity 'kidney disease' named entity 'caffeic acid' named entity 'MERS-CoV' named entity 'clinical trial' named entity 'COVID-19' named entity 'glycoprotein' named entity 'Human coronaviruses' named entity 'Fomite' named entity 'COVID' named entity 'triptolide' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'COVID-19' named entity 'phase I clinical trial' named entity 'healthcare systems' named entity 'Coronaviruses' named entity 'genetic code' named entity 'lopinavir' named entity 'repurposed drugs' named entity 'Inovio Pharmaceuticals' named entity 'viral life cycle' named entity 'closure of schools' named entity 'human clinical trials' named entity 'antibodies' named entity 'vaccine' named entity 'viral infections' named entity 'chloroquine' named entity 'virus replication'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software